The Psychedelics Gold Rush Meets Canadian Reality

For most of the past decade, psychedelic-assisted therapy has been a research story. Careful trials, cautious regulators, small clinics doing quiet work. This year it became a money story.

Recent reporting describes a wave of capital moving into the field from some of the most powerful investors in the world. Figures tied to the technology sector and to the current U.S. administration, a co-founder of PayPal, a co-founder of Google, the head of a leading artificial-intelligence lab, and others have backed psychedelic companies. Venture funds have raised dedicated pools of tens of millions of dollars. Large pharmaceutical companies have made billion-dollar acquisitions in the space. The signal is unmistakable: the money has decided psychedelics are going mainstream.

We think this is worth paying attention to, and worth thinking about carefully. Because capital is not the same as care, and attention is not the same as readiness.

What the money gets right

Some of this is genuinely good news. Serious money funds serious infrastructure. It pays for the large, rigorous trials regulators require. It supports manufacturing to pharmaceutical standards, practitioner training, and the unglamorous operational work that safe treatment depends on. For a field that has been chronically underfunded, institutional backing is a form of legitimacy, and legitimacy is what moves a therapy from the margins toward the people who might benefit from it.

A recent report from the U.S. Substance Abuse and Mental Health Services Administration (SAMHSA) captured the underlying reality well. It urged states to prepare now for the fiscal, legal, and operational implications of psychedelic therapies, and it reframed the central question. The question is no longer whether people will seek these treatments. They already are. The question is whether they will do so in regulated, supervised, safe settings, or in underground ones. That is exactly the right question, and it is the one that should guide policy on both sides of the border.

What the money cannot buy

Here is where we want to be honest, including about our own field.

Capital can build clinics. It cannot shorten the work that happens inside them. It can fund a trial, but it cannot guarantee the result. In 2024, U.S. regulators declined to approve one of the most closely watched MDMA-therapy applications, citing gaps in the clinical data. That decision was a reminder that enthusiasm, and funding, are not evidence. Rigour still gates approval, as it should.

More importantly, money can buy access to a molecule, but the molecule was never the whole treatment. The therapeutic relationship, thorough preparation, a genuinely safe setting, skilled support during the session, and real integration afterward are not decoration around the clinical core. They are the practice. A well-funded clinic staffed by undertrained people is not progress. A gold-rush mindset, which treats these medicines as a product to be scaled as quickly as possible, risks repeating the exact harms that careful, supervised care exists to prevent.

The Canadian picture is different

It is easy to read the American headlines and assume the same rules apply here. They do not.

In Canada, access to psychedelic-assisted therapy is not a matter of state-level legalization or a retail market. Psilocybin and MDMA remain restricted drugs. Legal patient access runs through Health Canada authorization considered on a case-by-case basis, initiated by a physician, and it is not guaranteed. These treatments are investigational, and authorization is generally reserved for specific, serious circumstances. No amount of investor enthusiasm changes that framework, and patients deserve to hear it plainly rather than to be swept up in a wave of hype that was written for a different country.

That gap between the headlines and the reality is precisely where people get hurt: not by the medicines themselves, but by expectations that outrun the evidence and the law.

What we keep coming back to

We have said before that the medicine is one ingredient among many. The billionaire moment does not change that. If anything, it makes it more important to say out loud.

The work that helps people is human work. It is a well-trained practitioner who can hold safety and connection at the same time. It is honest screening that turns some people away. It is preparation, informed consent, and the slow, patient labour of integration. None of that can be scaled by capital alone, and none of it should be.

So we welcome the money, cautiously, for what it can do: fund the science, build the infrastructure, and help push this care into regulated and safe settings rather than underground ones. And we will keep our attention on the part the money cannot reach. If psychedelic-assisted therapy is going to earn the mainstream credibility now being purchased for it, it will be because the care underneath is worthy of it.

The medicine is not the point. The people who deliver it, and the people who receive it, always were.